Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Apr 1.

Published in final edited form as: Mol Cancer Res. 2014 Jan 24;12(4):607–621. doi: 10.1158/1541-7786.MCR-13-0469

Characteristics of SC^med cells treated with CAF CM and Ac2-26 and grown under the renal capsule of NOD.SCID male mice in vivo. A, Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) images of representative untreated, CAF CM treated and Ac2-26 treated cE1 SC^med cells reveal the formation of glandular structures in CAF CM treated and Ac2-26 treated grafts. Treated grafts possessed increased basal and proliferating prostate cancer cells as analyzed by IHC for p63, CK8, AR, and Ki67. Images at 400× magnification. Bar 100 µm. B, Incidence of grafts with detectable glandular structures. C, Basal cell expansion was quantified from the number of p63⁺ cells per total cells per graft area and the ratio of p63⁺ cells to CK8⁺ cells per total cells per graft area. *, P < 0.05.

Characteristics of SC^med cells treated with CAF CM and Ac2-26 and grown under the renal capsule of NOD.SCID male mice in vivo. A, Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) images of representative untreated, CAF CM treated and Ac2-26 treated cE1 SC^med cells reveal the formation of glandular structures in CAF CM treated and Ac2-26 treated grafts. Treated grafts possessed increased basal and proliferating prostate cancer cells as analyzed by IHC for p63, CK8, AR, and Ki67. Images at 400× magnification. Bar 100 µm. B, Incidence of grafts with detectable glandular structures. C, Basal cell expansion was quantified from the number of p63⁺ cells per total cells per graft area and the ratio of p63⁺ cells to CK8⁺ cells per total cells per graft area. *, P < 0.05.

HHS Vulnerability Disclosure